Findings of a phase I/II study of nivolumab in patients with virus-associated tumours

New personalised therapies for lung cancer

Nivolumab and ipilimumab for metastatic sarcoma

Selumetinib in children with recurrent or refractory low-grade glioma

Dose escalation results of ceritinib and nivolumab for ALK NSCLC

Global health initiative oncology

Tivantinib as second line therapy for high-MET HCC

3 or 6 months adjuvant oxaliplatin for colorectal cancer

No link between pregnancy and breast cancer relapse

Larotrectinib shows durable efficacy across diverse paediatric and adult cancers

Routine genomic testing is feasible, but only a subset of patients benefit

Molecular profiles and the future of adjuvant therapy